Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - BRICS

BRICS

The Other Vaccines market in BRICS is anticipated to achieve a revenue of US$7.42bn by 2024.
It is projected to exhibit a Compound Annual Growth Rate (CAGR) of 10.87% between 2024 and 2029, leading to a market volume of US$12.43bn by 2029.
In terms of global comparison, United States is expected to generate the highest revenue, amounting to US$24,730.00m in 2024.
In Brazil, the demand for other vaccines is increasing due to the government's efforts to expand immunization coverage and prevent the spread of infectious diseases.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in BRICS has been experiencing significant growth in recent years, driven by several factors unique to each country.

Customer preferences: In Brazil, there has been a growing demand for vaccines to prevent diseases such as dengue fever, yellow fever, and meningitis. This is due to the country's tropical climate and high incidence of mosquito-borne illnesses. In Russia, there has been an increasing focus on vaccination against influenza, with the government implementing a national vaccination program. In India, there has been a rise in demand for vaccines against rotavirus and pneumococcal disease, as well as an increasing awareness of the importance of immunization. In China, there has been a growing interest in vaccines for human papillomavirus (HPV), as well as a focus on expanding access to vaccines in rural areas.

Trends in the market: In Brazil, the Other Vaccines market has been growing steadily due to the government's efforts to expand access to vaccines through the National Immunization Program. The market is also being driven by the increasing prevalence of infectious diseases such as dengue fever and yellow fever. In Russia, the market for Other Vaccines has been growing due to the government's focus on influenza vaccination, as well as increasing demand for vaccines against hepatitis B and pneumococcal disease. In India, the market for Other Vaccines has been growing rapidly due to the government's push to expand access to vaccines, as well as increasing demand for vaccines against rotavirus and pneumococcal disease. In China, the market for Other Vaccines has been growing due to the government's focus on expanding access to vaccines in rural areas, as well as increasing demand for vaccines against HPV.

Local special circumstances: In Brazil, the Other Vaccines market is heavily influenced by the government's National Immunization Program, which provides free vaccines to the population. In Russia, the market is heavily regulated by the government, which controls the prices of vaccines and determines which vaccines are included in the national vaccination program. In India, the market is highly fragmented, with a large number of domestic and international players competing for market share. In China, the market is dominated by domestic players, with foreign companies facing significant regulatory barriers to entry.

Underlying macroeconomic factors: The growth of the Other Vaccines market in BRICS is being driven by several underlying macroeconomic factors, including population growth, rising incomes, and increasing healthcare spending. In addition, the governments of these countries are investing heavily in healthcare infrastructure and expanding access to healthcare services, which is driving demand for vaccines. However, there are also significant challenges facing the Other Vaccines market in BRICS, including regulatory barriers, supply chain issues, and the high cost of vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.